Plasma exchange: the cost/benefit ratio and the critical revision of indications.
The number of conditions that can benefit from Plasma-Exchange (PE) continues to grow. We have recently added to the list the Cyclosporin-A induced hypertrygliceridemia and myoglobinuric acute renal insufficiency. Such as any therapeutic measure for PE, four evolutive phases can be recognized: the discovery and research, the confirmation of indications, the routine applications and the decline, when new more powerful tools are offered by culture or technology. We have participated in the first three phases during the last 20 years. Not necessarily all experiences were favourable. Nonetheless, we feel that, for the time being, a hemapheresis unit is an absolute necessity for a medium - sized hospital even if only therapeutic procedures are carried out. The phase four, decline of interest and applications, cannot be foreseen. Finally the ability of PE to shorten substantially the length of hospital stays along with the ease with which procedure can be performed on ambulatory patients, substantiate a favourable cost/benefit ratio for this therapeutic modality.
Immunohematology Division, San Martino Hospital, Genova, Italy.
M
M
Valbonesi
G
G
Florio
G
G
Lercari
P
P
Carlier
M R
MR
Ruzzenenti
R
R
Frisoni
D006801:Humans; D010951:Plasma Exchange / Q000009:adverse effects; D010956:Plasmapheresis / Q000009:adverse effects